{"entity":{"id":"azd9793","kind":"drug","name":"AZD9793","aka":[],"tldr":"AZD9793 is an experimental T-cell engager from AstraZeneca in phase 2 trials for hepatocellular carcinoma, aimed at Glypican-3.","summary":"AZD9793 is a T-cell engager developed by AstraZeneca. Its target is Glypican-3 (the sponsor names GPC3). The sponsor states: AZD9793 is a T-cell-engaging antibody that targets GPC3 on tumour cells, dosed intravenously and subcutaneously in the first-in-human RHEA-1 study, with a focus on hepatocellular carcinoma. ClinicalTrials.gov describes the intervention as: T cell-engaging antibody that targets GPC3 on tumour cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hepatocellular carcinoma. The largest, NCT06795022, plans to enrol 304 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AZD9793","url":"https://clinicaltrials.gov/search?intr=AZD9793"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":["gpc3"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06795022"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"T-cell engager","mechanism":"AZD9793 is a T-cell-engaging antibody that targets GPC3 on tumour cells, dosed intravenously and subcutaneously in the first-in-human RHEA-1 study, with a focus on hepatocellular carcinoma.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd9793/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"target":[{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct06795022","kind":"trial","name":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","route":"/trials/nct06795022/"}]}}